Overview
Phosphodiesterases (PDEs) are a family of enzymes that hydrolyze cyclic nucleotides (cAMP and cGMP), regulating intracellular signaling cascades. PDE5, the isoform targeted by sildenafil and tadalafil, is best known for its role in erectile dysfunction pharmacotherapy, but emerging evidence connects PDE inhibitors to broader biological effects including microbiome modulation.
Genomic and metabolomic analyses of sildenafil-treated patients reveal systemic metabolic shifts beyond the expected vascular effects, including altered bile acid and amino acid profiles that intersect with gut microbial metabolism ([1]). Bioinformatic approaches to erectile dysfunction have identified PDE-related pathways as nodes in networks connecting vascular function, inflammation, and microbial metabolite signaling ([2]).
In bacteria, phosphodiesterases serve as metal-sensing signaling enzymes, with metal cofactor availability (zinc, manganese) directly regulating cyclic-di-GMP turnover and, consequently, biofilm formation decisions. This positions PDEs at the intersection of host pharmacology and microbial ecology.
Cross-References
- erectile dysfunction — PDE5 inhibitor target condition
- biofilm — bacterial PDEs regulate biofilm via c-di-GMP
- zinc — metal cofactor for bacterial phosphodiesterases
- gut testis axis — metabolic connections between gut and male reproductive function